This cluster groups 2 independently calculated changes: Cash & equivalents increased 113.7%; Operating cash flow increased 54.3%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTGRI Bio, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 113.7%; Operating cash flow increased 54.3%.
2 evidence-backed componentsOperating cash flow changed +54.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
GRI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001824293-26-000057SEC ↗10-QAug 14, 2026Period Jun 30, 20260001824293-26-000055SEC ↗8-KJun 18, 2026Period Jun 18, 20260001824293-26-000050SEC ↗8-KMay 14, 2026Period May 14, 20260001824293-26-000046SEC ↗10-QMay 13, 2026Period Mar 31, 20260001824293-26-000044SEC ↗8-KFeb 4, 2026Period Feb 4, 20260001824293-26-000040SEC ↗10-KJan 30, 2026Period Dec 31, 20250001824293-26-000033SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 18, 2025Filed Sep 22, 2025 | Kelly LeanneChief Financial Officer | Grant Or AwardDirect | 43,222 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Current assets changed +103.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Total assets changed +100.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed -78.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed +43.1% from the comparable as-filed period.
Current ratio changed +326.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Cash & equivalents changed +113.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001824293-26-000030